Amgen (AMGN) FY2025 10-K Annual Report
Amgen (AMGN) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 13, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Amgen FY2025 10-K Analysis
Business Overview
- • Core business: Biopharmaceutical company focused on innovative therapies for serious illnesses
- • NEW segment emphasis: Integration and conversion of Horizon Therapeutics' equity plans post-acquisition in October 2023
- • Strategic shift: Acquisition of Horizon Therapeutics with stock plans merged, ending Horizon plans for future grants as of Oct 6, 2023
- • Quantitative metric: 11,230,989 total securities issuable under Amgen and acquired equity plans, weighted-average exercise price $234.45
- • Noteworthy fact: Performance units granted in 2023-2025 can yield up to 200% of target shares based on performance goals
Management Discussion & Analysis
- • Cash and equivalents $9.1B in 2025 vs $12.0B in 2024, decline of $2.9B
- • Long-term debt decreased to $50.0B in 2025 from $56.5B in 2024
- • Dividends per share increased 6% YoY to $2.38 in 2025 from $2.25 in 2024
- • No stock repurchases in 2025, $200M repurchased in 2024, $6.8B repurchase authorization remains
- • Management confident in liquidity from operations, debt markets, and existing cash for capital needs and shareholder returns
Risk Factors
- • Litigation risk: Ongoing U.S. Antitrust trial with Regeneron; jury awarded $135.6M compensatory damages, potential trebling to $406.8M total damages
- • Geopolitical exposure: Patent disputes in Germany and Japan with Sanofi and Regeneron, including upheld EP’004 patent validity and ongoing appeals
- • Supply chain/operational vulnerability: Multi-jurisdictional patent litigation delays marketing; UPC actions and EPO oppositions prolong product launches like Repatha and PAVBLU
- • Competitive risk: Multiple biosimilar patent infringement lawsuits filed against five companies including Amneal, Hikma, Dr. Reddy’s, Alkem seeking to enter U.S. market for Prolia/XGEVA
- • Financial risk: $1.8B final U.S. repatriation tax payment made in 2025 under 2017 Tax Act, material cash outflow impacting liquidity planning
Amgen FY2025 Key Financial MetricsXBRL
Revenue
$36.8B
▲ +10.0% YoY
Net Income
$7.7B
▲ +88.5% YoY
Operating Margin
24.7%
▲ +299bp YoY
Net Margin
21.0%
▲ +875bp YoY
ROE
89.1%
▲ +1947bp YoY
Total Assets
$90.6B
▼ -1.4% YoY
EPS (Diluted)
$14.23
▲ +88.2% YoY
Operating Cash Flow
$10.0B
▼ -13.3% YoY
Source: XBRL data from Amgen FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Amgen
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.